XRCC1基因多态性与结肠癌术后FOLFOX4化疗疗效相关性分析  

Relationship between polymorphism of XRCC1and FOLFOX4adjuvant treatment in colorectal cancer patients

作　　者：杨农[1] 仇宇[1] 王静[1] 周春花[1] 李坤艳[1] 林小平[1] 

机构地区：[1]湖南省肿瘤医院肿瘤内科,湖南长沙410013

出　　处：《中华肿瘤防治杂志》2013年第22期1736-1739,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的：分析XRCCl基因多态性与结肠癌术后FOLFOX4辅助化疗疗效的关系。方法：选择湖南省肿瘤医院2004-04—16—2006—10—25收治的76例结肠癌根治术后患者为研究对象，患者年龄25～75岁，中位年龄57岁，Ⅱ期20例，Ⅲ期56例，均接受FOLFOX4方案化疗6个周期，采取焦磷酸测序方法进行x射线修复交叉互补基因1（XRcCl）多态性分析，Cox模型分析结肠癌辅助化疗的疗效相关因素。结果：76例Ⅱ和Ⅲ期结肠癌患者的XRCCl-A399G位点存在3种等位基因型，其基因频率分别为G／G64．5％（49／76），G／A30．3％（23／76），A／A5．3％（4／76）。3年内复发26例，无瘤生存50例（65．8％）。其中G／G基因型49例患者中复发12例，G／A基因型23例患者中复发12例，A／A基因型4例患者中复发2例，G／G基因型复发率为24．5％，G／A＋A／A基因型为51．9％，差异有统计学意义，P=0．023。Cox模型单因素分析结果显示，TNM分期、壁浸润深度和XRCCl-A399G多态性与结肠癌FOLFOX4辅助化疗疗效有关，P〈0．05。而性别、年龄和病变部位与结肠癌FOLFOX4辅助化疗疗效无关，P〉0．05；Cox模型多因素分析显示，TNM分期是结肠癌FOLFOX4辅助化疗疗效独立预测因素。结论：XRCCl-A399G基因多态性与结肠癌FOLFOX4辅助化疗疗效有关。OBJECTIVE： By analyzing polymorphism of the XRCC1 gene to clarify the relationship between the poly- morphism of the XRCC1 gene and FOLFOX4 adjuvant chemotherapy in postoperative colon cancer patients. METHODS： A total of 76 postoperative colon cancer patients were enrolled,age from 21 to 75 years old,the median age was 57 years, included 20 phase ]I patients and 56 phase [ patients which all recived six cycles of FOLFOX4 adjuvant chemotherapy. The pyrophosphorie acid sequencing method was used to analyze polymorphism of XRCC1 and the Cox model was used to analyze the effect of FOLFOX4 adjuvant chemotherapy in colon cancer. RESULTS.. There were three allelotype of the XRCC1-A399G in 76 patients and gene frequency separately were G/G 64.5 % （49/76）,G/A 30.3 （23/76）, A/A 5.3 （4/76）. The relapse rate were 12/49 in G/G,12/23 in G/A,2/4 in A/A. The relapse rate of G/G genotype was less than that of G/A＋A/A genotype（24.5 % vs 51.9 .0, P 0. 023）. The single-factor-analytic of Cox model showed that there had relationship between TNM stage, depth of invasion, XRCC1-A399G polymorphism and curative effect of FOLFOX4 adjuvant chemotherapy（P0.05）. There had no relationship between sex,age, position and curative effect of FOLFOX4 adjuvant chemotherapy （P0.05）. The multiple-factor-analytic of Cox model showed that the TNM stage was an inde- pendent predictor of FOLFOX4 adjuvant chemotherapy in colon cancer patients. CONCLUSION.. There is relationship be- tween XRCC1-A399G gene polymorphism and curative effect of FOLFOX4 adjuvant chemotherapy.

关 键 词：XRCC1基因 多态性 结肠癌 奥沙利铂 5-氟尿嘧啶 药物疗法 联合 

分 类 号：R735.35[医药卫生—肿瘤]